Optimizing screening methods for nasopharyngeal carcinoma using EBV biomarkers
Official title: Comparison and Strategy Optimization of Plasma Epstein-Barr Virus (EBV) DNA and BNLF2b Total Antibodies (P85-Ab) with VCA-IgA and EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
Run by Sun Yat-sen University · NCT06870435 · Data updated 2026-11-12
This study is testing new ways to screen for nasopharyngeal cancer using blood tests for certain virus markers to see if they work better than the current methods for people at high risk.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 69 Years |
| Sex | All |
| Enrollment | 68649 (estimated) |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 1 site (Zhuhai, Guangdong) |
| Status | Recruiting |
| Started | January 24, 2025 |
| Main results expected | January 23, 2026 |
| Study ends | December 31, 2035 |
| Registry record updated | March 11, 2025 |
| Trial ID | NCT06870435 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged 30 to 69 years residing in Guangdong or Guangxi Province who are at high risk for nasopharyngeal carcinoma.
✕Probably not a fit
Patients with severe medical comorbidities, current malignant tumors, or significant organ dysfunction may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial is a prospective, self-controlled, multicenter investigation aimed at improving the screening strategies for nasopharyngeal carcinoma (NPC) in high-risk areas. Participants will be tested for various Epstein-Barr virus (EBV) associated biomarkers, including plasma EBV DNA and P85-Ab, alongside the standard two-antibody method. The study seeks to determine if these new testing methods can provide higher sensitivity while maintaining specificity compared to current practices. Additionally, novel biomarkers will be explored through next-generation sequencing and nasopharyngeal swabs to enhance screening accuracy.
Why it matters
Potential benefit: If successful, this study could lead to more effective and accurate screening methods for nasopharyngeal carcinoma, potentially improving early detection and patient outcomes.
How similar studies have gone: Other studies have shown promise in using EBV biomarkers for NPC screening, suggesting that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Voluntarily signed informed consent. * Age between 30 and 69 years at the time of screening. * Residents of Guangdong Province or Guangxi Province. * Able to cooperate with long-term follow-up. Exclusion Criteria: * Severe medical comorbidities, significant organ (heart, lung, liver, kidney) dysfunction, or psychiatric disorders. * Severe autoimmune diseases or immunodeficiency. * History of or current malignant tumors. * Inability to cooperate with the study due to psychological, social, familial, or geographical reasons.
Where it's running
-
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, China Recruiting
Study contacts
- Study coordinator: Ming-yuan Chen, MD, PhD
- Email: chmingy@mail.sysu.edu.cn
- Phone: 86-13903052650
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Structured swallowing exercises for nasopharyngeal cancer patients
This trial tests whether a structured swallowing exercise program improves swallowing and quality of life more than conventional swallowing exercises in adults with nasopharyngeal carcinoma.
-
Dynamic risk prediction for severe blood cell suppression in nasopharyngeal cancer
This study tests a dynamic risk model to see if it can predict grade 3 or higher anemia, low platelets, or low white blood cells during systemic therapy for adults with nasopharyngeal cancer.
-
Becotatug Vedotin plus PD-1 inhibitor for locally recurrent nasopharyngeal carcinoma
This study tests whether adding becotatug vedotin to a PD-1 inhibitor helps people with locally recurrent nasopharyngeal cancer.
-
Dynamic risk-guided EBV-DNA and MRI-based chemotherapy adjustments in nasopharyngeal carcinoma
This trial tests whether adjusting adjuvant therapy based on changes in EBV DNA and MRI findings after radiotherapy helps improve outcomes for people with nasopharyngeal carcinoma.
-
Immune Sandwich: Induction with Nimotuzumab and Toripalimab Plus Radiotherapy vs Full-Course Immunotherapy for Advanced Nasopharyngeal Cancer
This trial tests whether a shortened, targeted immunotherapy plan added to chemoradiation can match the full immunotherapy approach for locally advanced nasopharyngeal cancer in adults 18–70.
-
RAIRI-guided risk-stratified adjuvant therapy after chemoradiotherapy in nasopharyngeal carcinoma
This real-world study tests whether the RAIRI model can predict who will benefit from adjuvant therapy after chemoradiotherapy for non-metastatic nasopharyngeal carcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.